What question did this study set out to answer?

This study aims to review the pleiotropic effects of renal denervation beyond its role in lowering blood pressure.

June 28, 2026

Pleiotropic effects of renal denervation beyond blood pressure reduction

Q: What is the clinical evidence from this study?

Study design: Review. Population: Diseases characterized by sympathetic nervous system overactivation. Intervention: Renal denervation.

Key Result

Renal denervation may offer nephroprotective, hemodynamic, and metabolic benefits beyond blood pressure reduction in diseases characterized by sympathetic nervous system overactivation.

Key Points

This study aims to review the pleiotropic effects of renal denervation beyond its role in lowering blood pressure.
Analysis of preclinical studies and clinical trials on renal denervation effects.
Exploration of renal denervation's relationship with various diseases including heart failure and diabetes.
Evaluation of the potential nephroprotective effects and reduction in atrial fibrillation.
Renal denervation demonstrates nephroprotective effects and benefits in heart failure patients.
There are moderate improvements in glucose metabolism and reduced severity of obstructive sleep apnea associated with renal denervation.
Further clinical trials are needed to establish the significance and extent of these pleiotropic effects.

Structured PICO

Does renal denervation provide pleiotropic benefits beyond blood pressure reduction in patients with conditions characterized by sympathetic nervous system overactivation?

Population

Patients with conditions characterized by sympathetic nervous system overactivation, including hypertension, chronic kidney disease, heart failure, atrial fibrillation, type 2 diabetes mellitus, obstructive sleep apnea, and anxiety disorders

Intervention

Renal denervation (RDN)

Outcome

Pleiotropic effects beyond blood pressure reduction (including nephroprotection, hemodynamic and clinical effects in heart failure, reduction of atrial fibrillation burden, beneficial effect on glucose metabolism, and decreased severity of obstructive sleep apnea)

Renal denervation may offer pleiotropic benefits across multiple conditions driven by sympathetic overactivation, though definitive large-scale trials are still needed.

Limitations

Data are from a limited number of preclinical studies and clinical trials
Need for further well-designed, large-scale clinical trials to define the extent of these effects and clarify their clinical significance

Abstract

Overactivation of sympathetic nervous system (SNS) has a key role in the pathophysiology of hypertension, as well as in chronic kidney disease, heart failure, atrial fibrillation, type 2 diabetes mellitus, obstructive sleep apnea, and anxiety disorders. Renal denervation (RDN) has been proven to lower blood pressure (BP) in hypertensive patients by reducing SNS activity. Beyond hypertension, data from a limited number of preclinical studies and clinical trials suggest that RDN may also be nephroprotective, have beneficial hemodynamic and clinical effects in patients with heart failure, reduce the burden of atrial fibrillation, have a moderate beneficial effect on glucose metabolism, and decrease the severity of obstructive sleep apnea. This study reviews the potential pleiotropic effects of RDN in these diseases that are characterized by SNS overactivation, and highlights the need for further well-designed, large-scale clinical trials to define the extent of these effects, clarify their clinical significance, and determine how they relate to RDN-induced changes in blood pressure.

Bookmark